Subsequently, a vaccine was developed comprising six melanoma peptides presented by class II HLA-DR molecules, whose injection induced CD4+ T-cell responses in most melanoma patients and induced a clinical response in some patients [89]. This evidence concerns the gene CD4 and melanoma.